A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

NCT05753722 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors
Non Small Cell Lung Cancer
NSCLC

Interventions

BIOLOGICAL: PRTH-101
BIOLOGICAL: Pembrolizumab

Sponsor

Incendia Therapeutics